BACKGROUND: How hepatitis C virus (HCV) affects coronary heart disease (CHD) risk factors and outcomes is largely unknown. METHODS AND RESULTS: Among a cohort of patients with stable CHD, we examined the association between HCV seropositivity and levels of inflammatory markers (C-reactive protein [CRP], fibrinogen, interleukin-6, and tumor necrosis factor [TNF]-alpha) and risk for the following outcomes: death, cardiovascular (CV) events, and heart failure events. A total of 84 (8.6%) participants were found to be seropositive for HCV. HCV-seropositive patients were found to have significantly lower adjusted mean levels of CRP (2.6 vs. 4.4; P < .01) and fibrinogen (340 vs. 398; P < .01), but higher levels of TNF-alpha (7.1 vs. 4.8; P < .01). Age-adjusted rates for HCV seropositive vs. seronegative were as follows: death 93 vs. 42/1,000p-y (P < .01), CV events 62 vs. 40 (P=.13), and heart failure 76 vs. 29 (P < .01). After adjustment for demographic and clinical factors, HCV remained significantly associated with an increased risk for heart failure events (HR=2.13; 95% CI: 1.19-3.80). CONCLUSIONS: In this cohort with CHD, HCV seropositive participants had higher rates of death, CV events, and heart failure hospitalizations during follow-up. After adjustment for CV risk factors, HCV seropositivity remained independently associated with risk for heart failure events.
BACKGROUND: How hepatitis C virus (HCV) affects coronary heart disease (CHD) risk factors and outcomes is largely unknown. METHODS AND RESULTS: Among a cohort of patients with stable CHD, we examined the association between HCV seropositivity and levels of inflammatory markers (C-reactive protein [CRP], fibrinogen, interleukin-6, and tumor necrosis factor [TNF]-alpha) and risk for the following outcomes: death, cardiovascular (CV) events, and heart failure events. A total of 84 (8.6%) participants were found to be seropositive for HCV. HCV-seropositive patients were found to have significantly lower adjusted mean levels of CRP (2.6 vs. 4.4; P < .01) and fibrinogen (340 vs. 398; P < .01), but higher levels of TNF-alpha (7.1 vs. 4.8; P < .01). Age-adjusted rates for HCV seropositive vs. seronegative were as follows: death 93 vs. 42/1,000p-y (P < .01), CV events 62 vs. 40 (P=.13), and heart failure 76 vs. 29 (P < .01). After adjustment for demographic and clinical factors, HCV remained significantly associated with an increased risk for heart failure events (HR=2.13; 95% CI: 1.19-3.80). CONCLUSIONS: In this cohort with CHD, HCV seropositive participants had higher rates of death, CV events, and heart failure hospitalizations during follow-up. After adjustment for CV risk factors, HCV seropositivity remained independently associated with risk for heart failure events.
Authors: T Tsutamoto; T Hisanaga; A Wada; K Maeda; M Ohnishi; D Fukai; N Mabuchi; M Sawaki; M Kinoshita Journal: J Am Coll Cardiol Date: 1998-02 Impact factor: 24.094
Authors: D R Nelson; H L Lim; C G Marousis; J W Fang; G L Davis; L Shen; M S Urdea; J A Kolberg; J Y Lau Journal: Dig Dis Sci Date: 1997-12 Impact factor: 3.199
Authors: H Zylberberg; A C Rimaniol; S Pol; A Masson; D De Groote; P Berthelot; J F Bach; C Bréchot; F Zavala Journal: J Hepatol Date: 1999-02 Impact factor: 25.083
Authors: Shailja Shah; Yifei Ma; Rebecca Scherzer; Greg Huhn; Audrey L French; Michael Plankey; Marion G Peters; Carl Grunfeld; Phyllis C Tien Journal: AIDS Date: 2015-07-17 Impact factor: 4.177
Authors: Rosa Zampino; Aldo Marrone; Luciano Restivo; Barbara Guerrera; Ausilia Sellitto; Luca Rinaldi; Ciro Romano; Luigi E Adinolfi Journal: World J Hepatol Date: 2013-10-27
Authors: Paolo Maggi; Giuseppe Bruno; Francesco Perilli; Annalisa Saracino; Anna Volpe; Carmen Santoro; Nicoletta Ladisa; Gioacchino Angarano Journal: In Vivo Date: 2017-01-02 Impact factor: 2.155
Authors: Daniel Fuster; Debbie M Cheng; Emily K Quinn; David Nunes; Richard Saitz; Jeffrey H Samet; Judith I Tsui Journal: Addiction Date: 2013-10-24 Impact factor: 6.526
Authors: K W Chew; D Bhattacharya; T B Horwich; P Yan; K A McGinnis; C Tseng; M S Freiberg; J S Currier; A A Butt Journal: J Viral Hepat Date: 2017-04-10 Impact factor: 3.728
Authors: Luigi E Adinolfi; Rosa Zampino; Luciano Restivo; Amedeo Lonardo; Barbara Guerrera; Aldo Marrone; Fabio Nascimbeni; Anna Florio; Paola Loria Journal: World J Gastroenterol Date: 2014-04-07 Impact factor: 5.742